Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cl-amidine
- Development stage
- Preclinical
- Lead developer
- University of South Carolina
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor. It prevents histone 3 citrullination and neutrophil extracellular trap formation. Cl-amidine has been studied for its potential in treating conditions like lupus, cancer, and inflammatory diseases by inhibiting PAD enzymes, which are involved in various pathological processes.
- Other names
- Chlor-amidineN-α-benzoyl-N5-(2-chloro-1-iminoethyl)-l-ornithine amide
02
Targets
PADI1 (Peptidyl arginine deiminase 1)PADI3 (Peptidyl arginine deiminase 3)PADI4 (Peptidyl arginine deiminase 4)
Beyond the preview
Go deeper on cl-amidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cl-amidine.